Cannabidiorcol (CBD-C4) is a synthetic cannabinoid derivative that is structurally related to cannabidiol (CBD). It was first synthesized in 1978 and has been studied for its potential therapeutic effects, including anti-inflammatory and anti-convulsant properties. CBD-C4 has shown promise in preclinical studies, but further research is needed to determine its safety and efficacy for medical use.
Cannabinoids
- Abnormal cannabidiol
- Cannabidivarin
- O-1918
- Tetrahydrocannabiorcol
Research Studies
Laragione T, Harris C, Gulko PS (March 2023). Combination therapy of a TRPV2 agonist with a TNF inhibitor achieves sustained suppression of disease severity and reduced joint damage. Clinical and Experimental Immunology. 211 (3): 233–238. doi:10.1093/cei/uxac124. PMC10038320. PMID36571199.
Huang R, Li S, Tian C, Zhou P, Zhao H, Xie W, et al. (November 2022). Thermal stress involved in TRPV2 promotes tumorigenesis through the pathways of HSP70/27 and PI3K/Akt/mTOR in esophageal squamous cell carcinoma. British Journal of Cancer. 127 (8): 1424–1439. doi:10.1038/s41416-022-01896-2. PMC9553907. PMID35896815.
Cannabidiorcol Data Sources
| Reference | URL |
|---|---|
| Glossary | https:/glossary/cannabidiorcol |
| Wikipedia | https://en.wikipedia.org/wiki/Cannabidiorcol |
| Wikidata | https://www.wikidata.org/wiki/Q104249313 |
| Knowledge Graph | https://www.google.com/search?kgmid=/g/11ssmdr6rh |
| DBPedia | http://dbpedia.org/resource/Cannabidiorcol |
| Product Ontology | http://www.productontology.org/id/Cannabidiorcol |